Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients.

ABSTRACT:

SUBMITTER: Shen J 

PROVIDER: S-EPMC11814316 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature